To assess the contribution of αDG glycosylation to the progression of GBM and maintenance of a GSC phenotype, we employed an αDG mAb (IIH6) which specifically binds and blocks the ability of glycan moieties on αDG to bind laminin [20]. This evidence concerns the gene LAMB2 and glioblastoma.